Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

NCT ID: NCT00487786

Last Updated: 2016-01-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 64 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-06-30
• Study Completion Date: 2011-10-31

Brief Summary

This study is for patients with cancer who have failed potentially curative treatments or for whose disease a curative treatment does not exist.

OGX-427 is an antisense product that inhibits expression of one of the heat shock proteins. Decreasing this heat shock protein (Hsp27) should result in down regulation of pathways implicated in cancer progression and development of resistance to treatment.

Detailed Description

This study is for patients with breast, prostate, ovarian, non-small cell lung (NSCL) or bladder cancer who have failed potentially curative treatments or for whose disease a curative treatment does not exist.

OGX-427 is a second-generation ASO that inhibits expression of Hsp27. Hsp27 is one of the heat shock proteins. Hsp27 increases with cell stress, including cytotoxic chemotherapy, radiation therapy and hormone therapy and has been shown to inhibit cell death. Thus, decreasing Hsp27 as a cancer therapy is attractive as a therapy as it should result in down regulation of pathways implicated in cancer progression and development of resistance to treatment.

A number of in vitro and in vivo pharmacological studies have demonstrated that OGX-427 has single-agent activity in reducing Hsp27, inhibiting cell growth and inducing cell death in several human cancer cell lines. OGX-427 has also demonstrated chemosensitizing activity in studies using cell lines and animal models in combination with several cytotoxic drugs, including docetaxel.

Docetaxel (Taxotere®) has anticancer activity in breast, prostate, ovarian, non-small cell lung and bladder cancer. Docetaxel has been approved by Health Canada and the Food and Drug Administration for the treatment of patients with breast, prostate, ovarian and non-small cell lung cancer.

Conditions

Neoplasms

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

A

Each patient receives OGX-427

Group Type: EXPERIMENTAL

OGX-427

Intervention Type: DRUG

OGX-427 injection at 200mg, 400mg, 600mg, 800mg or 1000mg once a week until withdrawn

Docetaxel

Intervention Type: DRUG

injection - 75 mg/M2 IV on Day 1 every 21 days for cohorts 6 \& 7 only, together with appropriate dose of OGX-427 until withdrawn from study

Interventions

OGX-427

OGX-427 injection at 200mg, 400mg, 600mg, 800mg or 1000mg once a week until withdrawn

Intervention Type: DRUG

Docetaxel

injection - 75 mg/M2 IV on Day 1 every 21 days for cohorts 6 \& 7 only, together with appropriate dose of OGX-427 until withdrawn from study

Intervention Type: DRUG

Other Intervention Names

Taxotere

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years at time of consent.
• Histologically or cytologically confirmed diagnosis of one of the following: adenocarcinoma of the breast, ovary, or prostate, any NSCLC or bladder cancer.
• Must have metastatic disease. Prostate cancer patients must be hormone refractory.
• Must have failed therapies that are potentially curative; failed/refused standard therapy known to prolong survival or progression-free survival; or failed/refused therapy, that in the view of the investigator, would be beneficial in improvement of symptoms
• Patients enrolled into Cohorts 6 and 7 (OGX 427 in combination with docetaxel) must have disease that has a possibility of responding to docetaxel.
• A minimum of 28 days must have elapsed between any major surgery, the last dose of chemotherapy, radiotherapy (except limited fields-see #7 below), radioisotope, immunotherapy or experimental agent and enrollment onto the study. Note: Patients on hormone or estrogen therapy and steroids for treatment of their disease may remain on therapy.
• A minimum of 7 days must have elapsed between a single fraction of ≤ 800 cGy to a limited field or conventional radiotherapy to a limited non marrow-bearing field such as an extremity or orbit and enrollment onto the study.
• Recovery from all toxicities of prior therapy including chemotherapy, radiation therapy, immunotherapy and experimental agents to ≤ grade 2 by NCI CTCAE, version 3.0.
• If not treated with bilateral orchiectomy, patients with HRPC must be willing to continue luteinizing hormone releasing hormone (LHRH) analogues throughout the study.
• If taking opioid medication, patient must be willing to continue on the same opioid medication that they are on at enrollment through the PK/ECG evaluations during Cycle 1.
• Karnofsky score of ≥60%.
• Various laboratory requirements.
• Must be willing to use effective contraception during and for 3 months following treatment if of child bearing potential.
• Must be willing to undergo pharmacokinetic blood draws and frequent ECG monitoring on Days 1 and 2 of Cycle 1.
• Must provide written, informed consent.

Exclusion Criteria

• More than three cytotoxic chemotherapy regimens.
• Current treatment with any anticancer agent including but not limited to trastuzumab, aromatase inhibitors, or tamoxifen. Steroids, bisphosphonates and female hormone replacement therapy are allowed.
• Documented central nervous system (CNS) metastasis or carcinomatous meningitis.
• For patients in Cohorts 6 and 7, prior history of a serious allergic reaction to docetaxel; any chemotherapy containing Cremophor EL (used in drugs such as cyclosporine, etoposide, teniposide); or polysorbate 80 (the diluent for docetaxel).
• Current pregnancy or lactation.
• Current second malignancy except for non melanoma skin cancers, superficial bladder cancer, early cervical cancer or early prostate cancer not requiring treatment.
• Uncontrolled and/or serious medical conditions such as, but not limited to, active infection, symptomatic congestive heart failure, unstable angina, significant cardiac arrhythmia, significant neurological dysfunction, history of myocardial infarction or stroke within the 3 months prior to enrollment or any other condition which the Investigator feels would preclude protocol therapy.
• Concomitant participation in another clinical trial of an experimental drug, vaccine or device.
• Prior high dose chemotherapy requiring stem cell rescue.
• Atrial fibrillation, left bundle branch block, or obligatory use of a cardiac pacemaker.
• Currently on a drug known to increase the QTc duration.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Achieve Life Sciences

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kim Chi, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of British Columbia

Locations

Seattle Cancer Care Alliance

Seattle, Washington, United States

BC Cancer Agency

Vancouver, British Columbia, Canada

Juravinski Cancer Center

Hamilton, Ontario, Canada

Countries

United States; Canada

References

Chi KN, Yu EY, Jacobs C, Bazov J, Kollmannsberger C, Higano CS, Mukherjee SD, Gleave ME, Stewart PS, Hotte SJ. A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. Ann Oncol. 2016 Jun;27(6):1116-1122. doi: 10.1093/annonc/mdw068. Epub 2016 Feb 18.

Reference Type: DERIVED

PMID: 27022067 (View on PubMed)

Other Identifiers

OGX-427-01

Identifier Type: -

Identifier Source: org_study_id